Bio & Pharma
Handok gets Biocon's obesity drug exclusive distribution in S.Korea
The S.Korean company will sell liraglutide treatment, the main ingredient in Novo Nordisk's Saxenda, in the domestic market
By May 24, 2024 (Gmt+09:00)
1
Min read
Most Read
S.Korea's LS Materials set to boost earnings ahead of IPO process
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
Affirma Capital seeks to sell entire stake in both SeAH FS, S&G Holdings
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
SK asks KDB for further funding before drastic restructuring
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
EcoPro BM in talks to produce sodium-ion battery cathodes
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
Hyundai to transform Jeonju plant into hydrogen vehicle hub
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
![Handok gets Biocon's obesity drug exclusive distribution in S.Korea](https://www.kedglobal.com/data/ked/image/2024/05/24/ked202405240023.600x.0.jpg)
South Korean pharmaceutical company Handok Inc. announced on Friday that it signed an exclusive domestic sales and distribution agreement with India's global biotech company Biocon Ltd. for an obesity treatment containing liraglutide.
This treatment is a glucagon-like peptide-1 (GLP-1) analog based on synthetic peptide technology.
Liraglutide is the main ingredient in Saxenda, an obesity treatment by the Danish biotech company Novo Nordisk.
"Through collaboration with Biocon, we can expand our portfolio into the obesity sector. We will leverage our competitive edge as a leader in the diabetes business to successfully launch and grow this product," Chairman of Handok Kim YoungJin said.
Write to Jeong Min Nam at peux@hankyung.com
More to Read
-
Bio & PharmaHandok to import treatment for rare autoimmune disorder
Aug 31, 2023 (Gmt+09:00)
1 Min read -
Bio & PharmaHandok signs agreement with Microsoft Korea for digital transformation
Jan 17, 2023 (Gmt+09:00)
1 Min read
Comment 0
LOG IN